Sharon Bio-Medicine, a Rs. 1,075 crore pharma major, has posted strong growth of 21.4 per cent in consolidated net profit during the second quarter ended December 2013 to Rs. 16.20 crore from Rs. 13.35 crore in the corresponding half of the last year. Its consolidated net profit moved up by 34.3 per cent to Rs. 340.04 crore from Rs. 253.23 crore. And its EBDITA increased by 30.4 per cent to Rs. 38.74 crore from Rs. 29.72 crore. EPS worked out to Rs. 15.35 for the quarter.

The Board has decided to sub-divide its equity share of Rs. 10 each into five equity shares of the face value of Rs. 2 each and issue bonus shares in the ratio of 1:1 after sub-division. To accommodate additional shares the company is planning to increase its authorised share capital to Rs. 35 crore from Rs. 20.25 crore. Currently, Sharon Bio share of Rs. 10 each moving at Rs. 384 as against its yearly highest level of Rs. 457 on BSE.

For the first six month ended December 2013, Sharon's consolidated net sales increased by 39 per cent to Rs. 659.40 crore from Rs. 474.53 crore in the similar period of last year. Its net profit went up sharply by 25.1 per cent to Rs. 31.83 crore from Rs. 25.45 crore. EBDITA also improved by 31.7 per cent to Rs. 74.35 crore from Rs. 56.44 crore. EPS worked out to Rs. 30.16 as against Rs. 23.83 in the last period.